Last reviewed · How we verify
Tuberculosis Meningitis Treatment Adjunct — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Decadron | dexamethasone | Generic (originally Merck) | Corticosteroid [EPC] | Annexin A1, Interleukin-4, Androgen receptor | 1958-10-30 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Merck) · 1 drug in Tuberculosis Meningitis Treatment Adjunct
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Tuberculosis Meningitis Treatment Adjunct:
- Tuberculosis Meningitis Treatment Adjunct treatment updates — RSS
- Tuberculosis Meningitis Treatment Adjunct treatment updates — Atom
- Tuberculosis Meningitis Treatment Adjunct treatment updates — JSON
Cite this brief
Drug Landscape (2026). Tuberculosis Meningitis Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tuberculosis-meningitis-treatment-adjunct. Accessed 2026-06-10.
Related
- Tuberculosis Meningitis Treatment Adjunct full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing